Please login to the form below
Merck and Co.
This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
Moderna to acquire OriCiro Genomics for $85m
In December 2022, a personalised mRNA cancer vaccine from Moderna and Merck &Co – known as MSD outside the US and Canada – was shown to benefit patients with high-risk melanoma. ... In October 2022, the companies announced that Merck had exercised
Latest news
-
AZ and MSD launch ‘Never Miss’ for prostate cancer awareness
A new prostate cancer awareness campaign titled‘Never Miss’ has been launched by AstraZeneca (AZ) in partnership with MSD – known as Merck &Co in the US and Canada. ... also supporting them in feeling able to speak openly with family and friends.
-
AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza
The treatments are for use in prostate, biliary tract and advanced gastric cancer. ... The final recommendation was for AZ and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib) in combination with abiraterone and prednisone or
-
MSD’s Vaxneuvance approved by MHRA for prevention of pneumococcal diseases in children
MSD's – known as Merck &Co in the US and Canada – Vaxneuvance (PCV15) has been approved in the UK for the prevention of invasive disease, pneumonia and acute otitis media caused ... pre-term infants and children living with HIV infection or sickle
-
NICE rejects AstraZeneca and MSD’s Lynparza as NHS prostate cancer treatment
The National Institute for Health and Care Excellence (NICE) has rejected AstraZeneca (AZ) and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib), following an unsuccessful discussion ... has spread to other parts of the body and
-
AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
AstraZeneca (AZ) and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib) has been approved by the European Commission (EC) for the treatment of patients with germline ... The phase 3 trial is a double-blind, multicentre study
More from news
Approximately 44 fully matching, plus 523 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
By Sandy Lindsey. It’s little over a year since the bell first rang on the New York Stock Exchange announcing the arrival of Organon &Co, a spin-off from MSD ... known as Merck &Co in the US and Canada) with a mission to create improved health outcomes
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
-
AI: the smart money is on the smart thinking
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
-
Vertex: a vision of treating all CF patients worldwide draws closer
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.
Latest appointments
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
-
Weekly industry appointments
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
-
Nabriva Therapeutics appoints chief medical officer
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
-
Hansa Medical poaches Vifor Pharma’s CEO
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
-
Astellas promotes Anthony Fiordaliso to VP, Americas finance
He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president
More from appointments
Approximately 4 fully matching, plus 34 partially matching documents found.
Latest from PMHub
-
Practical Patient Centricity
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
-
Digital Marketing is no Substitute for Sound Strategic Marketing
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Meeting healthcare’s rising challenges
- Why female mentorship is so powerful in pharma
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
